NCT00087152View on ClinicalTrials.gov

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle

DRUG

Imatinib mesylate

400 mg by mouth daily

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00087152 - S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter